ArticleEuropean journal of nuclear medicine and molecular imaging2022
[
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Assessment of liver fibrosis and tumor burden in hepatocellular carcinoma using [European journal of nuclear medicine and molecular imaging · 2026Trial
- Non-specific uptake ofScientific reports · 2024Trial
- Value of [European journal of nuclear medicine and molecular imaging · 2026Article
- The diagnostic value of ⁶⁸Ga-FAPI PET/CT in patients with suspicious recurrent or metastatic differentiated thyroid cancer: a comparative study.BMC medical imaging · 2026Article
- [RMD open · 2026Article
- Preclinical evaluation and first-in-human study ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Head-to-head comparison of [Frontiers in medicine · 2026Article
- Diagnostic value of [Frontiers in oncology · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2025Article
- Different detection rates of brain metastasis in different pathological types of lung cancer byBMC cancer · 2025Article
- Distinguishing benign lesions from malignant ones using FAPI-based tracers: will we need to bid farewell to dual-time points imaging?European journal of nuclear medicine and molecular imaging · 2025Article
- Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation.Acta pharmaceutica Sinica. B · 2025Review
- Clinical comprehensive evaluation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Evaluating the diagnostic performance of [European radiology · 2025Article
- Cerebral [Translational stroke research · 2025Article
- Detecting radiation esophagitis usingBMC cancer · 2025Article
- Value of [European journal of nuclear medicine and molecular imaging · 2025Article
- Evaluating the diagnostic value ofJapanese journal of radiology · 2025Article
- Oxidant-free cross-dehydrogenative oxyalkylation enables late-stage functionalization of drugs.Innovation (Cambridge (Mass.)) · 2025Article
- Comparison of the diagnostic accuracy betweenJournal of thoracic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn this pilot study, we developed a new tracer, [
methodsIn vitro binding specificity of FAPI-04 to FAP was verified in U87 cells confocal of a fluorescence-labeled variant. In vivo imaging, competition, and dynamic scanning analyses were conducted to evaluate [
resultsBoth in vitro and in vivo results showed high binding specificity of FAPI-04 to FAP. High intratumoral uptake and fast body clearance of the tracer were observed in the xenograft mouse model and cancer patients. High-contrast images and negligible radiation exposure to normal tissue were observed on [
conclusion[
Indexed as
Identifiers
35262766What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.